Filters: Keyword is Cost-Benefit Analysis [Clear All Filters]
"AIDS Drug Assistance Programs: highlighting inequities in human immunodeficiency virus-infection health care in the United States." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 35, no. 5 (2002): 606-10. Abstract
"Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives?" Journal of the International AIDS Society 14 (2011): 38. Abstract
"Antiretroviral treatment and research in resource-poor countries." Lancet 361, no. 9355 (2003): 435.
"The case for routine HIV screening and impact of managed care." The American journal of managed care 16, no. 13 Suppl (2010): S345-51. Abstract
"The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa." Journal of acquired immune deficiency syndromes (1999) 56, no. 1 (2011): 26-35. Abstract
"Cost evaluation of evidence-based treatments." Addiction science & clinical practice 5, no. 2 (2010): 44-51. Abstract
"Cost-effectiveness of a community-based intervention for reducing the transmission of Schistosoma haematobium and HIV in Africa." Proceedings of the National Academy of Sciences of the United States of America 110, no. 19 (2013): 7952-7. Abstract
"Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients." Journal of acquired immune deficiency syndromes (1999) 43 Suppl 1 (2006): S113-8. Abstract
"Cost-effectiveness of buprenorphine and naltrexone treatments for heroin dependence in Malaysia." PloS one 7, no. 12 (2012): e50673. Abstract
"Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease." Journal of acquired immune deficiency syndromes (1999) 39, no. 1 (2005): 69-77. Abstract
"Cost-effectiveness of HIV screening for incarcerated pregnant women." Journal of acquired immune deficiency syndromes (1999) 38, no. 2 (2005): 163-73. Abstract
"Cost-effectiveness of HIV testing and treatment in the United States." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 45 Suppl 4 (2007): S248-54. Abstract
"Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India." PloS one 5, no. 9 (2010). Abstract
"Cost-effectiveness of HIV treatment as prevention in serodiscordant couples." The New England journal of medicine 369, no. 18 (2013): 1715-25. Abstract
"Cost-effectiveness of inhaled steroids in asthma: impact of effect on bone mineral density." The Journal of allergy and clinical immunology 117, no. 2 (2006): 359-66. Abstract
"Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model." The Journal of allergy and clinical immunology 120, no. 5 (2007): 1146-52. Abstract
"Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal." PLoS medicine 6, no. 10 (2009): e1000173. Abstract
"The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial." Drug and alcohol dependence 128, no. 1-2 (2013): 90-7. Abstract
"Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume." Archives of internal medicine 169, no. 12 (2009): 1113-21; discussion 1121-2. Abstract
"The cost-effectiveness of treatment for varicocele related infertility." The Journal of urology 168, no. 6 (2002): 2490-4. Abstract
"Dengue vector control strategies in an urban setting: an economic modelling assessment." Lancet 377, no. 9778 (2011): 1673-80. Abstract
"Economic costs of influenza-related work absenteeism." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 6, no. 2 (2003): 107-15. Abstract
"Evaluating interventions to improve antiretroviral adherence: how much of an effect is required for favorable value?" Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 13, no. 5 (2010): 535-42. Abstract
"Evaluating the cost-effectiveness of rabies post-exposure prophylaxis: a case study in Tanzania." Vaccine 27, no. 51 (2009): 7167-72. Abstract
"Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs." Annals of internal medicine 145, no. 11 (2006): 797-806. Abstract
"Expanded screening for HIV in the United States--an analysis of cost-effectiveness." The New England journal of medicine 352, no. 6 (2005): 586-95. Abstract
"First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial." AIDS (London, England) 25, no. 4 (2011): 479-92. Abstract
"HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 48, no. 6 (2009): 806-15. Abstract
"Incorporating quality of evidence into decision analytic modeling." Annals of internal medicine 146, no. 2 (2007): 133-41. Abstract
"Is antiretroviral therapy cost-effective in South Africa?" PLoS medicine 3, no. 1 (2006): e60.
"Lessons learned about behavioral science and acute/early HIV infection. The NIMH Multisite Acute HIV Infection Study: V." AIDS and behavior 13, no. 6 (2009): 1068-74. Abstract
"Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral." Medical decision making : an international journal of the Society for Medical Decision Making 25, no. 3 (2005): 321-9. Abstract
"Optimal frequency of CD4 cell count and HIV RNA monitoring prior to initiation of antiretroviral therapy in HIV-infected patients." Antiviral therapy 10, no. 1 (2005): 41-52. Abstract
"Optimizing financial incentives to improve health among military personnel: differences by pay grade and across branches." Preventive medicine 55 Suppl (2012): S116-7.
"The payoff time: a flexible framework to help clinicians decide when patients with comorbid disease are not likely to benefit from practice guidelines." Medical care 47, no. 6 (2009): 610-7. Abstract
"Potential cost-effectiveness of schistosomiasis treatment for reducing HIV transmission in Africa--the case of Zimbabwean women." PLoS neglected tropical diseases 7, no. 8 (2013): e2346. Abstract
"Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection." The American journal of medicine 115, no. 8 (2003): 632-41. Abstract
"Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines." Archives of internal medicine 162, no. 8 (2002): 921-8. Abstract
"Quantifying the decrement in utility from perceived side effects of combination antiretroviral therapies in patients with HIV." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 11, no. 5 (2008): 975-9. Abstract
"Resource utilization and cost-effectiveness of counselor- vs. provider-based rapid point-of-care HIV screening in the emergency department." PloS one 6, no. 10 (2011): e25575. Abstract
"Routine HIV screening in France: clinical impact and cost-effectiveness." PloS one 5, no. 10 (2010): e13132. Abstract
"Routine human immunodeficiency virus testing: an economic evaluation of current guidelines." The American journal of medicine 118, no. 3 (2005): 292-300. Abstract
"Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis." PLoS medicine 7, no. 12 (2010): e1000382. Abstract
"Social costs of robbery and the cost-effectiveness of substance abuse treatment." Health economics 17, no. 8 (2008): 927-46. Abstract
"State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards." Medical care 40, no. 5 (2002): 429-41. Abstract
"A study of financial incentives to reduce plasma HIV RNA among patients in care." AIDS and behavior 17, no. 7 (2013): 2293-300. Abstract
"The survival benefits of antiretroviral therapy in South Africa." The Journal of infectious diseases 209, no. 4 (2014): 491-9. Abstract
"Task force #2--the cost of prevention: can we afford it? Can we afford not to do it? 33rd Bethesda Conference." Journal of the American College of Cardiology 40, no. 4 (2002): 603-15.
"A therapeutic HIV vaccine: how good is good enough?" Vaccine 22, no. 29-30 (2004): 4044-53. Abstract
"When to start antiretroviral therapy in resource-limited settings." Annals of internal medicine 151, no. 3 (2009): 157-66. Abstract
